t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. [electronic resource]
Producer: 20060524Description: 1730-8 p. digitalISSN:- 0008-543X
- Adult
- Aged
- Antimetabolites, Antineoplastic -- adverse effects
- Antineoplastic Agents -- adverse effects
- Bone Marrow -- pathology
- Chromosomes, Human, Pair 21 -- drug effects
- Chromosomes, Human, Pair 3 -- drug effects
- Core Binding Factor Alpha 2 Subunit -- genetics
- DNA-Binding Proteins -- genetics
- Female
- Humans
- Hydroxyurea -- adverse effects
- Leukemia, Myeloid -- chemically induced
- Lymphocyte Activation -- drug effects
- MDS1 and EVI1 Complex Locus Protein
- Male
- Middle Aged
- Myeloproliferative Disorders -- drug therapy
- Neoplasm Proteins -- genetics
- Oncogene Proteins, Fusion -- analysis
- Proto-Oncogenes -- genetics
- Transcription Factors -- genetics
- Translocation, Genetic -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.